Advitech Solutions has published interim results for its ongoing open label clinical study for a psoriasis treatment based on its XP-828L product, a mix of growth factors extracted from whey protein. The main objectives of the study are to determine the safety and efficacy of the XP-828L, an oral treatment for psoriasis. Eleven patients were recruited for an initial eight-week study, and eight out of the 11 accepted to continue for an eight-week extension period. After the initial eight-week study, seven patients of 11, or 64%, showed a reduction in their psoriasis area and severity index (PASI) score compared with their baseline PASI score at day one; three have remained stable and the PASI score has increased for one patient. Safety data collected for all patients have shown no adverse reactions related to the use of the XP-828L product.